Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATYR
ATYR logo

ATYR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.790
1 Day change
-0.88%
52 Week Range
7.290
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Based on the data provided, ATYR is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows no significant positive catalysts, weak financial performance, and lacks strong technical or trading signals. Holding off on this stock is recommended for now.

Technical Analysis

The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 38.007, showing no clear overbought or oversold conditions. The stock price is below the pivot level of 0.82, with key support at 0.772 and resistance at 0.867. The overall trend is weak, with a high probability of further short-term declines.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data shows extremely low put-call ratios, indicating minimal bearish sentiment. However, the overall volume and open interest are low, suggesting limited trading activity and interest in the stock.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
0

Positive Catalysts

  • NULL identified. There is no recent news, no significant insider or hedge fund activity, and no congress trading data.

Neutral/Negative Catalysts

  • The stock has a high probability of declining further (-5.3% in the next week, -9.34% in the next month). Financial performance is weak, with declining net income (-6.71% YoY) and EPS (-22.22% YoY).

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$13.96M (down 6.71% YoY), and a significant EPS drop of -22.22% YoY. The gross margin remains at 100%, but this is not indicative of profitability given the net losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is provided. Wall Street sentiment appears neutral, with no strong opinions or recommendations on the stock.

Wall Street analysts forecast ATYR stock price to rise
2 Analyst Rating
Wall Street analysts forecast ATYR stock price to rise
0 Buy
2 Hold
0 Sell
Hold
Current: 0.792
sliders
Low
1
Averages
1
High
1
Current: 0.792
sliders
Low
1
Averages
1
High
1
Leerink
Faisal Khurshid
Outperform
maintain
$NULL
AI Analysis
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$NULL
AI Analysis
2025-09-15
maintain
Outperform
Reason
Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
2025-09-15
Reason
Cantor Fitzgerald
Price Target
2025-09-15
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ATYR
Unlock Now

People Also Watch